Brief Summary

The study utilizes a non-invasive deep brain stimulation (temporal interference, TI) technique primarily targeting the amygdala to preliminarily explore the clinical efficacy and potential mechanisms of MRI-compatible TI technology in regulating the amygdala in depressive disorders, providing a more comprehensive basis for the application of TI technology.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at P25-P50 for not_applicable major-depressive-disorder

Timeline
Completed

Started May 2024

Shorter than P25 for not_applicable major-depressive-disorder

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 27, 2024

Completed
4 days until next milestone

First Submitted

Initial submission to the registry

May 31, 2024

Completed
14 days until next milestone

First Posted

Study publicly available on registry

June 14, 2024

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 28, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 28, 2025

Completed
Last Updated

June 14, 2024

Status Verified

June 1, 2024

Enrollment Period

11 months

First QC Date

May 31, 2024

Last Update Submit

June 11, 2024

Conditions

Keywords

Major Depressive DisorderDeep Brain StimulationTI stimulation

Outcome Measures

Primary Outcomes (1)

  • HAMD-17

    Baseline, treatment completion day, 1 week, 4 weeks and 8 weeks

Secondary Outcomes (10)

  • HAMA

    Baseline, treatment completion day, 1 week, 4 weeks and 8 weeks

  • SHAPS

    Baseline, 4 weeks and 8 weeks

  • SF-36

    Baseline and 8 weeks

  • WHOQOL-BREF

    Baseline and 8 weeks

  • PSQI

    Baseline, 4 weeks and 8 weeks

  • +5 more secondary outcomes

Study Arms (1)

Amygdala TI

EXPERIMENTAL

Right amygdala Temporal Interference (TI) stimulation with 100 frequency difference, 20 minutes per day for 5 days.

Device: Nervio-X

Interventions

Nervio-XDEVICE

An 8-channel TIS device developed by NEURODOME Corporation.

Amygdala TI

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Participants must be aged between 18 and 65, with no gender restrictions;
  • A diagnosis of depression made by the study physician based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-5);
  • HAMD-17 score of 17 or higher;
  • Participants must not have changed their antidepressant medication regimen from 30 days prior to signing the informed consent form through the duration of the experiment;
  • Eligible individuals or their authorized representatives must demonstrate, as assessed by the study physician, a comprehensive understanding of the study's objectives and procedures, be capable of adhering to the requirements set forth in the study protocol, and provide their signature on the informed consent form.

You may not qualify if:

  • Eligible participants must not have a history of psychiatric or neurological disorders, as judged by the investigator, which may impact the evaluation of the study's efficacy;
  • Participants must not have a history of seizures or prior episodes of epilepsy;
  • The presence of metallic foreign objects within the cranial structure or metallic cardiac implants;
  • Participants must not have a diagnosis of organic brain disease, nor a history of significant cranial trauma or neurosurgical intervention;
  • Participants received electroconvulsive therapy or other physical therapies (such as transcranial magnetic stimulation therapy);
  • The researcher evaluated the individual's mental state and determined it to present a significant risk of suicidal ideation or behavior;
  • Pregnant or breastfeeding;
  • Participants who are concurrently engaged in other clinical interventional trials;
  • Participants presenting with other circumstances that the investigator deems unsuitable for the intervention being studied

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Shanghai Pudong New Area Mental Health Center

Shanghai, Shanghai Municipality, China

RECRUITING

MeSH Terms

Conditions

Depressive Disorder, Major

Condition Hierarchy (Ancestors)

Depressive DisorderMood DisordersMental Disorders

Central Study Contacts

Jingjing HUANG, MD PhD

CONTACT

Chencheng Zhang, MD PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chief Physician

Study Record Dates

First Submitted

May 31, 2024

First Posted

June 14, 2024

Study Start

May 27, 2024

Primary Completion

April 28, 2025

Study Completion

April 28, 2025

Last Updated

June 14, 2024

Record last verified: 2024-06

Data Sharing

IPD Sharing
Will not share

Locations